NOVO NORDISK INC.

Lobbying for NOVO NORDISK INC.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $1,300,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 1

S 150
Affordable Prescriptions for Patients Act of 2023

Lobbying activity 6

Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding.

Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill.

Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing.

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding.

Taxation/Internal Revenue Code

International and corporate tax issues.

Tariff (miscellaneous tariff bills)

Tariffs and trade policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.